EpiCept Reports Regulatory Progress On Ceplene(TM)
EbpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) reported that the assessment of its European Union centralized marketing authorization application for its lead oncology product Ceplene(TM) is advancing according to the anticipated regulatory timetable following a meeting yesterday. Ceplene (histamine dihydrochloride) has demonstrated important clinical benefit in the maintenance of remission for patients with Acute Myeloid Leukemia (AML).
